Form 4: Allogene Therapeutics Director Owen Witte Granted 95,400 Restricted Stock Units

Allogene Therapeutics, Inc. Director Owen N. Witte was granted 95,400 Restricted Stock Units (RSUs) on June 18, 2025, as disclosed in a recent SEC Form 4 filing.

Summary

• Owen N. Witte, a Director and 10% Owner of Allogene Therapeutics, Inc. (ALLO), was granted 95,400 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was June 18, 2025.
• Each RSU represents a contingent right to receive one share of the Company's Common Stock.
• The RSUs will vest in two successive equal semi-annual installments over a one-year period, measured from the grant date, contingent upon continued service.
• Mr. Witte has elected to defer the receipt of Common Stock upon vesting, in accordance with the Company's Non-Employee Director Compensation Policy, until either 30 days following separation from continuous service or a change in control of the Company.
• Following this transaction, Owen N. Witte beneficially owns 95,400 derivative securities (RSUs) directly.
• The filing also includes a Power of Attorney, dated June 17, 2024, authorizing specific individuals to execute Section 16 filings on behalf of Mr. Witte.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a routine disclosure, the grant of RSUs to a director aligns interests and incentivizes long-term commitment, which is generally viewed favorably. There are no negative surprises or adverse events reported.

Positives

• The grant of 95,400 Restricted Stock Units to a director aligns the director's interests with long-term shareholder value through equity-based compensation.
• The vesting schedule over one year encourages continued service and commitment from the director.
• The deferral election by the director indicates a long-term perspective on holding company stock.

Negatives

• The RSU grant, while a form of compensation, represents potential future dilution for existing shareholders upon conversion to common stock.
• There is no immediate cash inflow to the company from this RSU grant, as the acquisition price was $0.

Risks

• The vesting of RSUs is subject to continued service, meaning the director must remain with the company for the RSUs to convert to shares.
• The value of the RSUs upon vesting is dependent on the future market price of Allogene Therapeutics' common stock, introducing market risk.

Future Outlook

The Restricted Stock Units are set to vest in two equal semi-annual installments over a one-year period from the grant date of June 18, 2025, subject to the director's continued service. The receipt of common stock upon vesting is deferred until 30 days following separation from service or a change in control.

Industry Context

This RSU grant is a standard practice in the biotechnology and pharmaceutical industry for compensating non-employee directors, aligning their long-term interests with the company's performance and shareholder value. It reflects a common approach to executive and director compensation in publicly traded companies.

Comparison to Industry Standards

• The grant of equity-based compensation like RSUs to non-employee directors is a common practice across the biotech and broader corporate landscape, comparable to compensation structures at companies like Gilead Sciences, Amgen, or Regeneron Pharmaceuticals, which also utilize equity awards to incentivize long-term commitment.
• The vesting schedule of one year with semi-annual installments is a typical short-to-medium term vesting period for director equity grants, similar to practices observed in many S&P 500 companies for non-executive directors.
• The deferral option for stock receipt upon vesting is a common feature in director compensation policies, allowing directors to manage tax implications and align with personal investment strategies, consistent with corporate governance best practices.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Owen N. Witte, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential future dilution upon RSU conversion, but also benefit from aligned director incentives.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership.
• Management: No direct impact mentioned, but the Power of Attorney streamlines SEC filing processes for the legal/compliance team.

Next Steps

• The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from June 18, 2025.
• The reporting person will receive common stock upon vesting, subject to their deferral election, which will occur either 30 days following separation from continuous service or upon a change in control of the Company.

Key Dates

Keywords

Allogene Therapeutics, ALLO, Restricted Stock Units, RSU, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Stock Award, Beneficial Ownership